Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma
Highly malignant tumors overexpress the minichromosome maintenance 2 (MCM2) protein in the nucleus, which is associated with advanced tumor grade, advanced stage, and poor prognosis. In this study, we showed that MCM2 is highly expressed in clinical samples of ovarian clear cell carcinoma. Although MCM2 expression was mainly localized to the nuclei as in other cancers, a few cases exhibited cytoplasmic localization of MCM2. Surprisingly, tumor samples with cytoplasmic MCM2 demonstrated excellent prognosis, showing 100% survival during the observation period of more than 200 months. However, cases with nuclear expression of MCM2 exhibited approximately 78% 5-year-survival rate. In a previous study, we showed that Friend leukemia virus (FLV) envelope protein gp70 bound to MCM2, impaired its nuclear translocation, and enhanced DNA damage-induced apoptosis in FLV-infected hematopoietic cells with high levels of MCM2. As expected, clear cell carcinoma cells with cytoplasmic expression of MCM2 exhibited significantly higher apoptotic cell ratio than that of cells with nuclear MCM2 expression. In vitro experiments using ovarian cancer cells with cytoplasmic expression of MCM2 demonstrated that transfection of MCM2-ΔN enhanced DNA damage-induced apoptosis. Therefore, cytoplasmic localization of MCM2 significantly correlated with increased apoptosis in clear cell carcinoma cells, resulting in improved prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Oncotarget - 9(2018), 46 vom: 15. Juni, Seite 28213-28225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aihemaiti, Gulinisha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer therapy target |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.25613 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286063689 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286063689 | ||
| 003 | DE-627 | ||
| 005 | 20231225050818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.25613 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0953.xml |
| 035 | |a (DE-627)NLM286063689 | ||
| 035 | |a (NLM)29963273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aihemaiti, Gulinisha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Highly malignant tumors overexpress the minichromosome maintenance 2 (MCM2) protein in the nucleus, which is associated with advanced tumor grade, advanced stage, and poor prognosis. In this study, we showed that MCM2 is highly expressed in clinical samples of ovarian clear cell carcinoma. Although MCM2 expression was mainly localized to the nuclei as in other cancers, a few cases exhibited cytoplasmic localization of MCM2. Surprisingly, tumor samples with cytoplasmic MCM2 demonstrated excellent prognosis, showing 100% survival during the observation period of more than 200 months. However, cases with nuclear expression of MCM2 exhibited approximately 78% 5-year-survival rate. In a previous study, we showed that Friend leukemia virus (FLV) envelope protein gp70 bound to MCM2, impaired its nuclear translocation, and enhanced DNA damage-induced apoptosis in FLV-infected hematopoietic cells with high levels of MCM2. As expected, clear cell carcinoma cells with cytoplasmic expression of MCM2 exhibited significantly higher apoptotic cell ratio than that of cells with nuclear MCM2 expression. In vitro experiments using ovarian cancer cells with cytoplasmic expression of MCM2 demonstrated that transfection of MCM2-ΔN enhanced DNA damage-induced apoptosis. Therefore, cytoplasmic localization of MCM2 significantly correlated with increased apoptosis in clear cell carcinoma cells, resulting in improved prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MCM2 | |
| 650 | 4 | |a cancer therapy target | |
| 650 | 4 | |a clinicopathologic study | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a pathology | |
| 700 | 1 | |a Kurata, Morito |e verfasserin |4 aut | |
| 700 | 1 | |a Nogawa, Daichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Mineo, Tatsunori |e verfasserin |4 aut | |
| 700 | 1 | |a Onishi, Iichiroh |e verfasserin |4 aut | |
| 700 | 1 | |a Kinowaki, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Xiao-Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Tatsuzawa, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Miyasaka, Naoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Masanobu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Kouhei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 9(2018), 46 vom: 15. Juni, Seite 28213-28225 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2018 |g number:46 |g day:15 |g month:06 |g pages:28213-28225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.25613 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2018 |e 46 |b 15 |c 06 |h 28213-28225 | ||